Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $3.8 million.

  • Gyre Therapeutics' Net Cash Flow rose 121364.99% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 96201.38%. This contributed to the annual value of -$21.4 million for FY2024, which is 34818.12% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Net Cash Flow is $3.8 million, which was up 121364.99% from $21.4 million recorded in Q2 2025.
  • Gyre Therapeutics' Net Cash Flow's 5-year high stood at $52.7 million during Q1 2021, with a 5-year trough of -$52.3 million in Q3 2022.
  • In the last 5 years, Gyre Therapeutics' Net Cash Flow had a median value of -$3.8 million in 2024 and averaged -$977842.1.
  • In the last 5 years, Gyre Therapeutics' Net Cash Flow plummeted by 37239.29% in 2021 and then skyrocketed by 121364.99% in 2025.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Net Cash Flow stood at -$14.8 million in 2021, then crashed by 81.57% to -$26.9 million in 2022, then surged by 174.15% to $19.9 million in 2023, then crashed by 119.05% to -$3.8 million in 2024, then skyrocketed by 198.82% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $21.4 million for Q2 2025, and $3.2 million during Q1 2025.